Toxicity of oxaliplatin rechallenge in metastatic colorectal cancer

Affiliations

¹ Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy; Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy.
² Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy.
³ Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy; Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy. Electronic address: salvatore.siena@unimi.it.

Free article

Comment

G Mauri et al. Ann Oncol. 2018.

Free article

. 2018 Oct 1;29(10):2143-2144.

doi: 10.1093/annonc/mdy306.

¹ Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy; Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy.
² Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy.
³ Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy; Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy. Electronic address: salvatore.siena@unimi.it.

No abstract available

Comment on

Beyond second-line therapy in patients with metastatic colorectal cancer: a systematic review.
Arnold D, Prager GW, Quintela A, Stein A, Moreno Vera S, Mounedji N, Taieb J. Arnold D, et al. Ann Oncol. 2018 Apr 1;29(4):835-856. doi: 10.1093/annonc/mdy038. Ann Oncol. 2018. PMID: 29452346 Free PMC article.